These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 5119325)

  • 1. A simple and rapid gas chromatography for determining 3,4-dihydroxyphenylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid in urine from patients with parkinsonism treated with L-3,4-dihydroxyphenylalanine.
    Fukaya J; Imai K; Tamura Z
    Clin Chim Acta; 1971 Jul; 33(2):470-2. PubMed ID: 5119325
    [No Abstract]   [Full Text] [Related]  

  • 2. The simultaneous determination by selected ion monitoring of the levels of homovanillic, isohomovanillic, 3,4-dihydroxyphenylacetic and 3-methoxy-4-hydroxymandelic acids in single biological samples.
    Narasimhachari N; Leiner K; Brown C
    Clin Chim Acta; 1975 Jul; 62(2):245-53. PubMed ID: 807438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

  • 4. Tyrosine metabolism: urinary excretion studies in Parkinsonism.
    Szpunar WE; Ericsson AD; McCann DS
    Clin Chim Acta; 1971 Nov; 35(1):209-17. PubMed ID: 5126994
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring phenylalanine-tyrosine metabolism by high-resolution liquid chromatography of urine.
    Mrochek JE; Dinsmore SR; Ohrt DW
    Clin Chem; 1973 Aug; 19(8):927-36. PubMed ID: 4720815
    [No Abstract]   [Full Text] [Related]  

  • 7. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 9. Simultaneous separation of acid metabolites of catecholamines: application to urine and tissue.
    Messiha FS; Bakutis E; Frankos V
    Clin Chim Acta; 1973 Apr; 45(2):159-64. PubMed ID: 4736744
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 11. The metabolism of orally administered L-Dopa in Parkinsonism.
    Calne DB; Karoum F; Ruthven CR; Sandler M
    Br J Pharmacol; 1969 Sep; 37(1):57-68. PubMed ID: 5343357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental and clinical studies on catecholamine metabolism. I. Determination of urinary homovanillic acid (3-methoxy-4-hydroxyphenylacetic acid) and vanillylmandelic acid (3-methoxy-4-hydroxymandelic acid)].
    Takahashi E
    Nihon Naibunpi Gakkai Zasshi; 1970 Aug; 46(5):539-51. PubMed ID: 5465953
    [No Abstract]   [Full Text] [Related]  

  • 13. m-Hydroxyphenylacetic acid formation from L-dopa in man: suppression by neomycin.
    Sandler M; Karoum F; Ruthven CR; Calne DB
    Science; 1969 Dec; 166(3911):1417-8. PubMed ID: 5350345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 16. IV. Estimation by gas chromatography of urinary homovanillic acid and vanilmandelic acid in neuroblastoma.
    Williams CM; Greer M
    Methods Med Res; 1970; 12():106-14. PubMed ID: 5432487
    [No Abstract]   [Full Text] [Related]  

  • 17. [Qualitative analysis of the main urinary metabolites of dopamine, epinephrine and norepinephrine by gas chromatography].
    Bègue RJ; Bazerolle O; Desgres J; Lallemant C; Padieu P
    Pathol Biol (Paris); 1971; 19(15):719-25. PubMed ID: 4942503
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose-related alterations in metabolism of levodopa: possible mechanism for hypotensive effect.
    Kochar MS; Itskovitz HD; Sasse EA; Baker JD; Doumas BT
    J Clin Pharmacol; 1974; 14(8):448-54. PubMed ID: 4851433
    [No Abstract]   [Full Text] [Related]  

  • 19. Separation and determination of urinary homovanillic acid and iso-homovanillic acid by gas-liquid chromatography and electron capture detection.
    Dziedzic SW; Dziedzic LB; Gitlow SE
    J Lab Clin Med; 1973 Nov; 82(5):829-35. PubMed ID: 4746822
    [No Abstract]   [Full Text] [Related]  

  • 20. The biochemistry of catecholamines in relation to Parkinson's disease.
    Hinterberger H
    Aust N Z J Med; 1971 May; 1():Suppl 1:14-8. PubMed ID: 5292808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.